TIMELINE

TIMELINE

2026

 
June 9, 2026
Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma
 
May 30, 2026 
2026-ASCO-A phase II study of FOLFIRINOX (FFX) combined with the glycogen synthase kinase-3beta (GSK-3β) inhibitor elraglusib (ELRA) and the transforming growth factor beta (TGFβ) inhibitor losartan (LOS) in patients with untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)
 
May 30, 2026 
2026-ASCO-Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma
 
May 11, 2026
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
 
April 3, 2026 
2026-AACR-Inhibition of GSK3β signaling in pediatric brain tumors
 
March 9, 2026
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
 
January 21, 2026
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
 
January 6, 2026
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
 

2025

 
 
October 22, 2025 
2025-AACR-NCI-EORTC-The glycogen synthase kinase-3β inhibitor 9-ING-41 in combination with chemoimmunotherapy provides long-term survival in the Th-MYCN mouse model
 
July 17, 2025
Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas
 
June 24, 2025
Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial
 
May 28, 2025
2025-ASCO-Machine learning and statistical prediction of overall survival (OS) from pre-dose plasma biomarkers in a randomized phase 2 trial (1801 Part 38) of the GSK-3 inhibitor elraglusib with gemcitabine/nab-paclitaxel (GnP) in metastatic pancreatic ductal adenocarcinoma (mPDAC): application toward patient enrichment
 
May 6, 2025
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer
 
April 4, 2025 
2025-AACR-Elraglusib, a glycogen synthase kinase-3β (GSK-3β) inhibitor, plus chemotherapy with or without immunotherapy for advanced salivary gland cancer

February 25, 2025
Actuate Announces Completion of Enrollment in a Phase 2 Trial of Elraglusib in Combination with FOLFIRINOX and Losartan in Patients with Previously Untreated Metastatic Pancreatic Cancer

January 7, 2025
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer
 

2024

 
December 17, 2024

Positive Interim Phase 2 Data of Elraglusib in pancreatic cancer

August 14, 2024

Initial Public Offering

August 1, 2024
FDA Orphan Drug Designation for Elraglusib
 
February 9, 2024
The Last Patient’s First Dose of Elraglusib in pancreatic cancer
 
January 2024
Completion of Enrollment in Phase 2 clinical study in pancreatic cancer
 

2023

 
August 14, 2023
Completion of Phase 1 Trial for Oral Formulation of Elraglusib 
 
 

2022

 
February 7, 2022

Initiation of FOLFIRINOX Trial

 

2021

 
August 4, 2021

Actuate announces FDA fast track designation for 9-ING-41 in the treatment of pancreatic cancer.

October 27, 2021

Actuate announces the primary endpoint was met in the 9-ING-41 Phase 2 study in pancreatic cancer.

 

2020

 
July 31, 2020

Actuate announces initiation of Phase 2 clinical study in pancreatic cancer.

 

2018

 
February 15, 2018

The FDA accepts Actuate’s IND application for 9-ING-41 with clearance to proceed with clinical study in patients with advanced cancers.

December 17, 2018

Actuate treats first patient in Phase 1 / 2 Clinical Study of 9-ING-41 in patients with refractory cancers.

 

2017

 
March 31, 2017

Actuate technologies are featured in the Molecular Pathways section of the journal Clinical Cancer Research.

August 18, 2017

FDA grants 9-ING-41 an additional orphan drug designation for the treatment of neuroblastoma.

 

2016

 
March 29, 2016

Food and Drug Administration grants 9-ING-41 an orphan drug designation for the treatment of glioblastoma.

 

2015

 
January 16, 2015

The company is incorporated as Apotheca Therapeutics, Inc.

October 29, 2015

Actuate forms a Scientific Advisory Board.

 

Partnering

As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations.

COLLABORATE WITH US